GCP ClinPlus offers end-to-end clinical development services in neuroscience, with a strong focus on Alzheimer's disease, depression, and rare neurological disorders such as SMA and ALS. Equipped with China CNS CRO-specific cognitive assessment tools (e.g., ADAS-Cog) and CSF biomarker testing protocols, we address common challenges such as placebo effect bias and endpoint variability. With deep therapeutic expertise and operational excellence, we help sponsors advance safe and effective neurological therapies through every stage of development.

Delivering What Matters to Biopharma

With a deep commitment to innovation and patient-centered research, GCP ClinPlus is a proven China Neurology CRO partner in the neuroscience space.

Delivering What Matters to Biopharma

Our neuroscience team has delivered over 100 studies across indications, including Alzheimer's disease, ALS, ataxia, Parkinson's disease, multiple sclerosis, epilepsy, brain tumors, migraines, and CNS infections.

We offer industry-leading operational models tailored to the unique demands of neurology research, including:

CNS-specific assessment tools (e.g., ADAS-Cog) and CSF biomarker strategies

Flexible, fast-adapting trial designs that overcome placebo effect challenges

Robust data capture and real-time analytics to ensure insight-rich outcomes

Streamlined project timelines, from study start-up to data lock

Dedicated CNS teams offering deep neurological expertise and proactive support

Our CNS trials emphasize scientific precision, patient safety, and global regulatory readiness. Having supported 11 CNS drug approvals—including one for Alzheimer's disease—we're trusted by both global and domestic sponsors to drive neurological innovations forward.

For more information about Neurodegenerative Disease CRO, please feel free to contact us!

There are many clinical development companies, but we are the best choice for you.